Drug Profile
Shigella vaccine - AVANT
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Developer Celldex Therapeutics Inc
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Shigella infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Shigella-infections in USA (PO)
- 18 Jul 2008 Preclinical development is ongoing
- 01 Aug 2006 This compound is still in active development